<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1323">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01695200</url>
  </required_header>
  <id_info>
    <org_study_id>DSRB: 2011/00028</org_study_id>
    <nct_id>NCT01695200</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acids in Autism Spectrum Disorders</brief_title>
  <official_title>The Role of Omega-3 Fatty Acids in the Management of Singaporean Children With Autism Spectrum Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Healthcare Group, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Healthcare Group, Singapore</source>
  <oversight_info>
    <authority>Singapore: Health Sciences Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12-week open label trial to evaluate whether omega-3 fatty acids is effective in
      reducing the severity of autism and its comorbidities.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in parent rated Social Responsiveness Scale (SRS) scores during treatment</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in parent rated Child Behavior Checklist (CBCL) scores during treatment</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in teacher rated Teacher Report (TRF) scores during treatment</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in teacher rated Social Responsiveness Scale (SRS) scores during treatment</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in clinician rated Clinical Global Impression (Severity and Improvements) scores during treatment</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in clinician rated Global Assessment of Functioning (GAF) scores during treatment</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's Yale-Brown Obsessive Compulsive Scale modified for Pervasive Developmental Disorders (CYBOCS-PDD)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of plasma fatty acid composition, measurements of DHA and EPA (components of omega-3), and total phospholipid count</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of dietary intake and nutritional intake of the child</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Autism Spectrum Disorders</condition>
  <arm_group>
    <arm_group_label>Omega-3 Fatty Acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15ml omega-3 liquid form, twice a day for 12 weeks (Total daily dosage:840mg DHA and 192mg EPA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 fatty acids</intervention_name>
    <arm_group_label>Omega-3 Fatty Acids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between ages 5 and 18 years old

          -  Diagnosed to have Autism, Asperger Syndrome, or PDDNOS by the DSM-IV criteria; met
             the Autism or Spectrum classification for Autism Diagnostic Interview - Revised
             (ADI-R) and Autism Diagnostic Observation Schedule (ADOS)

          -  Written parental consent for participation

          -  Those not on current standard-of-care treatments for ASD

        Exclusion Criteria:

          -  Below 5 and above 18 years old

          -  No formal diagnosis of Autism, Asperger Syndrome or PDD-NOS

          -  Without written parental consent for participation

          -  Those with brain pathology such as serious head injury, epilepsy, etc.

          -  Those on current standard-of-care treatment for ASD

          -  Those with psychotic symptoms, self-injurious behaviours and/or suicidal tendency,
             and other history of clinically significant medical conditions screened by the
             attending doctor to have increase the risk associated with study participation

          -  Those on other types of medication or supplements or with change in dose
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Sung, MBBS, MMed</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Healthcare Group, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Mental Health</name>
      <address>
        <city>Singapore</city>
        <zip>168937</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 30, 2013</lastchanged_date>
  <firstreceived_date>September 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Healthcare Group, Singapore</investigator_affiliation>
    <investigator_full_name>Dr. Sung Min</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
